CERo Therapeutics Holdings, Inc. - Common Stock (CERO)
14.96
-4.87 (-24.56%)
NASDAQ · Last Trade: Jun 18th, 9:58 AM EDT
Detailed Quote
Previous Close
19.83
Open
14.38
Bid
14.92
Ask
15.00
Day's Range
14.32 - 15.70
52 Week Range
0.3600 - 44.77
Volume
873,233
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
3,773,991
Chart
About CERo Therapeutics Holdings, Inc. - Common Stock (CERO)
CERo Therapeutics Holdings, Inc. is a biotechnology company that focuses on developing innovative therapies for serious medical conditions through advanced gene editing technologies. By leveraging proprietary platforms, the company aims to create transformative treatments that target the root causes of diseases, particularly in areas where current therapies are limited or lacking. CERo Therapeutics is dedicated to improving patient outcomes and advancing the field of precision medicine by working collaboratively with research institutions and healthcare professionals to ensure its solutions meet the highest standards of efficacy and safety. Read More
Peraso Inc. (NASDAQ: PRSO), a leader in millimeter wave (mmWave) wireless technology, has announced the initial production shipments of its next-gen 60 GHz wireless communication platform, marking a major step into the global tactical communications and battlefield safety market.
CERo Therapeutics Holdings Inc (NASDAQ:CERO) shares are trading higher Tuesday after the company received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for CER-1236.
SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that deploy phagocytic mechanisms, announces that the U.S. Food and Drug Administration (FDA) has granted CERo’s Orphan Drug Designation (ODD) for the company's lead drug candidate CER-1236, for the treatment of acute myeloid leukemia (AML). CER-1236 is an innovative therapy that engineers a cancer patient's own T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells.
SOUTH SAN FRANSCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced that its board of directors has determined to effect a one-for-twenty reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has issued additional shares of its Series D Preferred Stock to certain institutional investors (the “Investors”) pursuant to the securities purchase agreement previously entered into by and between the Company and such Investors on April 22, 2025 with respect to the issuance of shares of Series D Preferred Stock for an aggregate purchase price of up to $8 million, including $5 million previously issued in April 2025 and up to $3 million issuable at the option of the Investors. The shares of Series D Preferred Stock are convertible into shares of the Company’s common stock.
